Pamela R. Contag

Pamela Contag, Ph.D., has a career as a biopharmaceutical entrepreneur, researcher and senior executive that spans more than 25 years. Dr. Contag co-founded BioEclipse Therapeutics™, initially named ConcentRX, raising seed funding and licensing key patents from Stanford University with a mission to deliver transformative, safe and precise therapies for resistant and recurrent cancers regarded as virtually untreatable. As CEO of the company, she was named by Goldman Sachs as one of the 100 Most Intriguing Entrepreneurs of 2018, and in 2019, she successfully led BioEclipse through the completion of its Series A financing. Previously, Dr. Contag served as a senior executive for several pioneering biomedical technology companies, including Cygnet Biofuels, Cobalt Technologies and Xenogen Corp., which she co-founded based on technology she developed during her post doctorate training. As CEO of Xenogen from 1995 to 2006, Dr. Contag led the company’s successful initial public offering, grew U.S. and international revenue and built a customer base that included many leading pharmaceutical companies.

In 2004, Xenogen was named one of the top 100 fastest growing companies by the San Francisco Times and received the Frost and Sullivan Technology Innovations award. Dr. Contag was recognized as one of the “Top 25 Young Businesses” by Fortune Small Business in 2000, followed in 2001 and 2003 with the R&D 100 award for achievements in Physics. Dr. Contag was also named one of the “Top 25 Women in Small Business” by Fortune magazine. She was also awarded the Northstar Award from Springboard Enterprises. While she served as CEO and Chairman of Cobalt Technologies, the company was named one of the top 20 cleantech companies. In 2011, Dr. Contag was awarded “Cleantech Innovator of the Year” award for technology developed at Cygnet Biofuels.

With more than 25 years of microbiology research experience, Dr. Contag is widely published in the field of Microbiology and Optical Imaging and has over 35 patents in Biotechnology. Dr. Contag received her Ph.D. in Microbiology from the University of Minnesota Medical School in 1989 studying Microbial Physiology and Genetics (for Alternative Fuels), and completed her postdoctoral training at Stanford University School of Medicine in 1993 specializing in “Host/Pathogen Interactions.”